IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11369577 B1

PDFFull Text
Date of Patent:
Jun. 28, 2022

Filed:

Nov. 25, 2015

Reprogramming-based models of neurodevelopmental disorders and uses thereof

Applicants:

Ieo—istituto Europeo Di Oncologia S.r.l., Milan, IT;

I.r.c.c.s. “casa Sollievo Della Sofferenza”, San Giovanni Rotondo, IT;

Università Degli Studi Di Milano, Milan, IT;

Inventors:

Giuseppe Testa, Milan, IT;

Sina Atashpazgargari, Milan, IT;

Antonio Adamo, Milan, IT;

Pierre-Luc Germain, Milan, IT;

Giuseppe Merla, Milan, IT;

Giuseppe D'Agostino, Milan, IT;

Matteo Zanella, Milan, IT;

Assignees:

IEO—Istituto Europeo di Oncologia S.r.l., Milan, IT;

I.R.C.C.S. “Casa Sollievo della Sofferenza”, San Giovanni Rotundo, IT;

Università degli Studi di Milano, Milan, IT;

Attorney:

Knobbe, Martens, Olson & Bear, LLP

Primary Examiner:

Jeffrey S Lundgren

Assistant Examiner:

Michael J Schmitt

Int. Cl.
CPC ...
A61K 31/00 (2006.01); G01N 33/50 (2006.01); C12N 5/074 (2010.01); C12Q 1/6881 (2018.01); C12Q 1/6883 (2018.01); A61K 31/421 (2006.01); A61K 31/135 (2006.01); C12Q 1/6897 (2018.01);
U.S. Cl.
CPC ...
A61K 31/00 (2013.01); A61K 31/135 (2013.01); A61K 31/421 (2013.01); C12N 5/0696 (2013.01); C12Q 1/6881 (2013.01); C12Q 1/6883 (2013.01); G01N 33/5058 (2013.01); G01N 33/5073 (2013.01); C12N 2501/06 (2013.01); C12N 2501/115 (2013.01); C12N 2501/13 (2013.01); C12N 2501/60 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/608 (2013.01); C12N 2501/727 (2013.01); C12N 2503/00 (2013.01); C12N 2503/02 (2013.01); C12N 2506/1307 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15041 (2013.01); C12Q 1/6897 (2013.01); C12Q 2600/158 (2013.01);
Abstract

The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.

Find Patent Forward Citations

Loading…